Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine vs Active Placebo for Severe Depression and Suicide
NCT03666390Phase 2Unknown
- Sponsor
- Taipei Veterans General Hospital
- Start
- Sep 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in major depressive disorder (MDD) and suicidal ideation (2 arms), sponsored by Taipei Veterans General Hospital. Primary endpoint: Reduction rate of suicide symptom at 14 days. Status: unknown.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)suicidal ideation
Beyond the preview
Go deeper on NCT03666390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03666390.